The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ross is a seasoned biotech pro and you can guarantee he is working up something significant in the background.
The data shows they have something nobody else does.
They also have a world class stem cell production facility in Wales which alone is worth 3-5 times current market cap.
I checked the limits and noticed you could not buy 250k online so to me this drop and the mm's were making out it looks terrible when infact there is not that much stock out there and they are trying to cause panic so I took 150k max at 4p. Just a trade if it spikes I will probably take a quick profit but I thought it was very oversold anyway
Last two trading days has seen a buyer come into Reneuron. Someone has started to build a position. £2million market cap now makes this a real takeover target.
I'm interested in views from our more informed members here as to whether this announcement in the budget as reported today in the Economist could be helpful to ReNeuron. The article sub headed |"Britain commits to finding a regulatory route for customised genetic medicines" the article stated - "The headlines about the autumn statement from Jeremy Hunt, the chancellor, this week focused on tax and spending. But tucked away in the written documents was news that could transform the cutting-edge of medicine. The Medicines and Health-care products Regulatory Agency (mhra) is working with Genomics England, Oxford University and Mila’s Miracle Foundation, a charity, to develop a regulatory pathway to allow one-off drugs to be designed and approved for use in individual patients in less than a year.
Medicines currently travel a well-worn route to market comprising two or three phases of trials in large groups of patients. But this approach is impossible for the vast majority of genetic disorders, which are often vanishingly rare or even unique. The technology to customise medicines for people with such conditions exists but the regulatory route they must take is rocky.....etc" Couls this be an additional encouragement to get a deal across the line and what Ian has been waiting for? Surely this must offer some hope to striking one or more DEALS, PARTNERSHIPS, INVESTMENT, ASSET REVALUATION. THose with better knowledge maybe able to provide greater insight here PLEASE COMMENT IF SO. The link to the article is: https://www.economist.com/britain/2023/11/22/the-worlds-first-pathway-for-individually-designed-drugs?utm_campaign=a.the-economist-today&utm_medium=email.internal-newsletter.np&utm_source=salesforce-marketing-cloud&utm_term=11/22/2023&utm_id=1830040 THANK YOU.
I think you’re right. One of those alleged’ sells’ was my purchase of 3,000 shares for the princely sum of £106 ish. I’m desperate to average down or perhaps lose another £106 on top of the thousands already invested!
I'm currently being offered 3.55 to buy and 3.556 to sell. I know it's only a slight difference but am wondering if all of today's 3.55's are in fact buys and not sells as indicated by LSE trade app?
It was more likely a delayed sell. Maybe tell tomorrow in holding rns. How many more months cash have these got ?
Either we are seeing one of the main holders approaching their exit, which often involves a fairly violent period of activity near the conclusion (and thus hopefully on fumes now), or the old forward selling game.
If we soon see an announcement of a discounted placing, then that may tell a story.
Sorry to come across as cynical, but I have seen too many...patterns on AIM to dismiss such a scenario.
Perhaps always merely a coincidence? Who knows? Not my job to police it, and nothing I can do about it, so no point wasting time on it.
IMO, Iain and the team either have something that is of commercial value, or they do not. And I think they have pretty much had enough time now to demonstrate this, one way or the other.
So, if we are indeed looking at a raise, it would have to be extremely compelling to retain my support at this point.
Huge inside buying, for a start. And not just Iain. Absolute clarity on the parameters, including time frames etc. The level of dilution and share price would also be a big consideration for me, regardless of the other factors.
But hopefully it is just the first scenario.
The current cash runway is ample if a deal/deals are really just on the horizon IMO.
That is a chunky purchase and goes directly against the current sentiment of selling off RENE.
It is such a large and positive statement that I'm wondering if we'll see more of the same tomorrow.
Chester.
I need a price of £ 1.20 to break even I feel for you . I looks like death by a thousand cuts not much time left to resolve the cash issue.
Yes they did do a consolidation of 1/100, I need £5 a share to break even!
Nothing new probably six months at the most before liquidity comes to force, they need to pull a rabbit out of the hat, not a rat as I suspect, good luck Ian this is the last throw of the dice.
Did $Rene do a 1/100 reverse split a few years back? If so, are they going to become the first company to end up a lower unit stock price than they had before the split?
Nope. We need one well before then realistically.
And an update on developments fairly soon too, I think. GLA.
Just been reading the RNS. £5.1m in the bank and £5.6m equivalent annual cash burn. So basically we have until summer to get a deal it seems.
If the market believed that deals were a given, there is simply no chance that the SP would be around 5p right now.
Well, you can never say never of course, so let's say 90% probability, if not 100%.
If I thought that deals were a given, I would be a buyer right now.
As it is, I am just holding, because I have not written Iain off yet - but we need an upfront cash deal PDQ. And I do not think that statement requires an 'IMO'.
You could assume deals are a given, as we're told the trials that have produced the positive data have been funded by the entities that ReNeuron would be partnering with.
As LWHL says, if they do sign terms (anyone's guess how likely that is) then it could result in one of the biggest days for any AIM share ever, given how low a starting point we're at now. £1 a share still only values the company at less than £60m, which is really very little.
Pure speculation what the share price could be of course, but a £60m market cap doesn't sound unreasonable to me if they can achieve terms similar to what others have agreed with equivalent (inferior?) preclinical data. To be clear, I'm not ramping or saying it's going to ten or twenty bag etc etc, it may very well go bust, and people need to be abundantly aware of that, if they somehow weren't already.
As a gamble on them getting a deal/deals.
Potential multibagger if they do. We know the outcome if they do not.
Can anybody tell me as to why at this moment people would invest in Rene. Every avenue has been exhausted, there is nowhere to go
At this stage, only industry partners (and up front cash) will do. GLA.
Next up, partner deals. There is nothing else to come. Industry partners, hopefully, rather than academic.
Unfortunately it speaks volumes that the BOD has bought bugger all.
This latest work should not be underestimated in my view. Reneuron has clearly demonstrated, in vivo, payload delivery to specific tissues and without an immune response. This is what precision medicine is supposed to be all about.
The implication of their extensive work on stem cell lines and exosomes is that, in all likelyhood, all adult tissues retain a 'memory' of their stem cell origin which forms the basis for addressable access ; for classic cell-to-cell communication and for any therapies that can exploit it.
How many stem cell lines will be required to map the whole human body? Probably quite a lot, but Reneuron has begun to read/write this developmental atlas. They may even have enough stem cell lines to treat /target some conditions already.
The big pharma companies are sitting on huge piles of cash whilst their portfolios go off patent. They are pro- precision medicine too. I just hope they wake up and see this company is gold dust, or at least worth a punt. I will continue to invest here. Good luck all ,and, as ever, DYOR.
It is not much of a surprise that Allenby Capital are upbeat on the share they after all are the brokers for the company.